300896 Imeik Technology Development
- 219.88
- +9.06+4.30%
Imeik Technology Development News
Aimeike (300896): 24Q1 net profit YOY +27.38% performance in line with expectations
Incident Overview The company released its report for the first quarter of 2024. 24Q1 achieved revenue of 808 million yuan, +28.24% year over year; net profit to mother of 527 million yuan, +27.38% year over year; net profit without return to mother 5.28
Aimeike (300896): 2024Q1 Earnings Review: Performance Meets Expectations, Expectations for Core Products to Drive Growth
Incident: The company recently announced its 2024 quarterly report. The 24Q1 revenue was 81 million yuan/+28% year over year, and net profit to mother was 530 million yuan/year over year +27%. The increase in revenue performance was in line with expectations, and the performance was close to the forecast limit (this
Express News | The concept of computing power continues to ferment, and many leading telecommunications companies have received intensive research from institutions
Aimeike (300896): Profitability remains high, and the pipeline is expected to be realized one after another
Guide to this report: Profitability remains high, and is expected to be realized one after another in the research pipeline. It is optimistic about long-term growth space and maintains an increase in holdings rating. Key investment points: Maintain an increase in holdings rating. The company's 2024Q1 revenue was 808 million yuan (+28.24%)
Aimeike (300896): High growth, high profits, and a rich pipeline of products under development
Incident The company released its 2023 annual report and 2024/1 quarterly report: 2023 revenue of 2,869 billion yuan (+48.0% year over year), net profit to mother of 1,888 billion yuan (+47.1% year over year), deducted from Africa
Aimeike (300896): A steady start to 24Q1, good physical growth, and the release of recycled products
Core view Under a high base, the company started well. In 24Q1, revenue increased by 28.2% and +15.6% month-on-month, while net profit attributable to mother and net profit after deduction of 27.4% and 36.5% increased by 27.4% and 36.5%, which is at the top of the performance forecast range. which
China Post Securities released a research report on April 26 stating that it gave Aimeike (300896.SZ) a purchase rating. The main reasons for the rating include: 1) the high boom in the industry and high revenue growth from January to February '24; 2) gro
China Post Securities released a research report on April 26 stating that it gave Aimeike (300896.SZ) a purchase rating. The main reasons for the rating include: 1) the high boom in the industry and high revenue growth from January to February '24; 2) gross margin declined slightly, the cost ratio was optimized during the period, and the net interest rate remained high. (Mainichi Keizai Shimbun)
Aimeike (300896): Steady improvement of core products and orderly layout of new products to jointly build a performance moat
Investment highlights: The company released the 24Q1 financial report. The performance is in the middle of the forecast, in line with market expectations. According to the company announcement (same below), the 24Q1 company's revenue was 808 million yuan, an increase of 28.24% over the previous year; net profit to mother was 5.27
Cinda Securities released a research report on April 25 stating that it gave Aimeike (300896.SZ) a purchase rating. The main reasons for the rating include: 1) excellent revenue growth, significant rate optimization, and non-recurrent factors slightly dis
Cinda Securities released a research report on April 25 stating that it gave Aimeike (300896.SZ) a purchase rating. The main reasons for the rating include: 1) excellent revenue growth, significant rate optimization, and non-recurrent factors slightly disrupt net interest rates; 2) expecting to continue to provide revenue growth after new products are approved/gradually released. (Mainichi Keizai Shimbun)
The quarterly report verifies the strong growth in performance, why is Aimeike (300896.SZ) making strong players stronger?
In recent years, with the improvement of living standards, people have begun to pursue a higher level of spiritual life, and the face value economy has made great strides. According to a report published by Tencent Marketing Insights, the Chinese medical beauty market has grown at a compound annual growth rate of 17.5% since 2017 to nearly 190 billion dollars in 2021. However, due to multiple factors such as changes in residents' income expectations, the growth rate of medical and aesthetic consumption began to slow in 2022. The Zhitong Finance App notes that under the pessimistic expectations of the market, medicine and beauty have been questioned a lot over the past year or so as an “improved” optional consumption.
Aimeike (300896): Non-net profit increased by 37% after Q1, core products continued to grow
Performance review 1Q24 results reached the upper limit of the forecast range, in line with our expectations. The company announced 1Q24 results: revenue of 808 million yuan, +28.2% year-on-year, net profit of 527 million yuan, net profit to mother of 527 million yuan, +27.4% year-on-year, deducted
Qunyi Securities released a research report on April 25 stating that it maintains the Aimeike (300896.SZ) Buy (Buy) rating. The main reasons for the rating include: Performance summary: In 2024Q1, revenue of 810 million yuan was achieved, a year-on-year i
Qunyi Securities released a research report on April 25 stating that it maintains the Aimeike (300896.SZ) Buy (Buy) rating. The main reasons for the rating include: Performance summary: In 2024Q1, revenue of 810 million yuan was achieved, a year-on-year increase of 28.2%, and recorded net profit of 530 million yuan, an increase of 27.4% over the previous year, after deducting 530 million yuan of post-profit, an increase of 36.5% over the previous year. The difference was mainly due to changes in fair value profit and loss. The performance was in line with expectations. (Mainichi Keizai Shimbun)
Aimeike (300896): 24Q1 Hi-Sports series revenue grew rapidly
The 24Q1 performance maintained relatively rapid growth. The 24Q1 company with strong growth resilience achieved revenue of 808 million yuan/yoy of 28.24%, and net profit of 527 million yuan/yoy 27.38%. Net profit not returned to mother withheld 5
Aimeike (300896): Net profit returned to mother increased 27% in the first quarter, and product matrix construction progressed steadily
Earnings grew steadily in the first quarter, and major products continued to expand in scale. The company's revenue for the first quarter of 2024 was 808 million yuan, up 28.24% year on year, and net profit to mother was 527 million yuan, up 27.38% year on year, deducted
Amex (300896): Core products drive growth
Matters: 24Q1 achieved revenue of 808 million yuan, up 28.24% year on year and 15.60% month on month; net profit to mother was 527 million yuan, up 27.38% year on year, up 19.83% month on month; deducted
Aimeike (300896) 24Q1 financial report review: Net profit from return/non-return to mother is biased forecast, Shangyuan expects the core pipeline to maintain excellent growth & the gradual expansion of new pipelines
Incident: The company released its 2024 quarterly report: the company achieved revenue of 808 million yuan/yoy +28.2% in 24Q1, net profit of 527 million yuan/yoy +27.4%, net profit of non-return to mother of 5.28
Ameke (300896): Q1 results are close to forecast, and the increase in upstream holdings shows long-term confidence
Event: The company released its report for the first quarter of 2024. 1) 2024Q1 achieved revenue of 850 million yuan, a year-on-year increase of 28%; achieved net profit of 530 million yuan, a year-on-year increase of 27%; achieved deduction of 5.3 million yuan
Express News | Aimeike: Net profit from mother for the first quarter was 527 million yuan, up 27.38% year-on-year
Amex (300896): Performance is in line with expectations, growth potential continues to be unleashed
Performance Overview On April 24, 2024, the company released its report for the first quarter of 2024. In 1Q24, the company achieved revenue of 808 million yuan (+28%) and net profit of 527 million yuan (+27%) to mother, deducted
Aimeike (300896): Using Technology to Make Adults Beautiful
Grasping the long-term upward direction of medicine and aesthetics, I am optimistic that leading domestic manufacturers will lead market segment growth dividends, and there is a certain correlation between medical and aesthetic spending and residents' income expectations, yet the growth pace of upstream medical and aesthetic manufacturers at home and abroad is not frequent. The pursuit of health and beauty is eternal for humans
Analysis
Price Target
No Data
